OncoMatch/Clinical Trials/NCT07323056
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Is NCT07323056 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sacituzumab Tirumotecan and Limertinib for egfr-mutant non-small cell lung cancer.
Treatment: Sacituzumab Tirumotecan and Limertinib — This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinical treatment plans and enabling patients to receive the optimal treatment regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
Disease stage
Required: Stage IIIA, IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR tyrosine kinase inhibitor
Patients who have received any EGFR-TKI...treatment before
Cannot have received: antibody-drug conjugate
Patients who have received any...TROP2 ADC treatment before
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07323056 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIA or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages